Clinical Trials on Metastatic Urothelial Cancer

Total 55299 results

Gilead Sciences
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (TROPHY U-01)

Metastatic Urothelial Cancer

Italy, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
Matthew Galsky
Bristol-Myers Squibb; Hoosier Cancer Research Network

Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States, Canada
Ectin Research AB

Not yet recruiting

A Study of MFA-370 in Patients With Metastatic Urothelial Cancer (MANHATTAN)

Metastatic Urothelial Cancer

Sweden
Matthew Galsky
Icahn School of Medicine at Mount Sinai; AstraZeneca

Completed

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Metastatic Urothelial Cancer

United States
University Hospital, Ghent

Completed

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

Belgium
Monika Joshi, MD
Pfizer; Eisai Inc.; Big Ten Cancer Research Consortium

Terminated

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Metastatic Urothelial Cell Cancer

United States
Orion Biotechnology Polska Sp. z o.o.

Not yet recruiting

Study of OB-002 in Patients With Refractory Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
Astellas Pharma China, Inc.
Seagen Inc.

Active, not recruiting

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Metastatic Urothelial Cancer

China
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (IMAGINE)

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditions

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
National Cancer Institute (NCI)

Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
Advaxis, Inc.

Terminated

A Study of ADXS-NEO Expressing Personalized Tumor Antigens (NEO)

Metastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer Metastatic

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Latin American Cooperative Oncology Group
Janssen-Cilag Ltd.

Completed

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Recurrent/Metastatic Urothelial Cancers

Brazil
Institut Claudius Regaud

Completed

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function. (VEFORA)

Metastatic Urothelial Cancer | Advanced Urothelial Cancer

France
Associació per a la Recerca Oncologica, Spain
Pivotal S.L.; Merck, S.L., Spain

Completed

Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma (INDUCOMAIN)

Metastatic Urothelial Cancer

Spain
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Cancer

Japan
Icahn School of Medicine at Mount Sinai

Recruiting

Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors

Metastatic Solid Tumor | Urothelial Cancer

United States
Associació per a la Recerca Oncologica, Spain
Takeda; Pivotal S.L.

Unknown

Paclitaxel and TAK-228 in Urothelial Carcinoma

Metastatic Urothelial Cancer

Spain
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States, Australia, Georgia
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Advanced and Metastatic Urothelial Cancer

Spain, United States, France
Sandy Srinivas
GlaxoSmithKline

Completed

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Bladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer | Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

United States
Bernie Eigl
Lady Davis Institute; Vancouver Prostate Centre; Bladder Cancer Canada

Recruiting

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Metastatic Urothelial Carcinoma | Metastatic Bladder Cancer

Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III... and other conditions

United States, Canada
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
UNICANCER

Completed

EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies (EXPRESS)

Metastatic Cancers

France
Consorzio Oncotech

Completed

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study (ARIES)

Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Italy
National Cancer Institute (NCI)

Recruiting

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Platinum-Resistant Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Metastatic Urethral Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Ureter Cancer AJCC v7 | Stage IV Urethral Cancer AJCC v7 | Ureter Urothelial Carcinoma and other conditions

United States, Canada
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)

Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast Cancer

Japan
University of Utah
Exelixis

Active, not recruiting

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

Bladder Cancer | Metastatic Urothelial Carcinoma

United States
University of Utah
National Cancer Institute (NCI)

Suspended

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE)

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid Variant

United States
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
Emory University
National Cancer Institute (NCI); Exelixis

Recruiting

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

Metastatic Cancers

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast (VARIA-DCE-US)

GIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic Cancer

France
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
Dana-Farber Cancer Institute
Gilead Sciences

Active, not recruiting

Sacituzumab Govitecan Plus EV in Metastatic UC

Bladder Cancer | Urothelial Cancer | Metastatic Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter

United States

Clinical Trials on Metastatic Urothelial Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations